Trevena Stock Forecast, Price & News

Trevena (NASDAQ:TRVN) Frequently Asked Questions

Is Trevena a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Trevena stock.
View analyst ratings for Trevena or view top-rated stocks.

How has Trevena's stock price been impacted by COVID-19 (Coronavirus)?

Trevena's stock was trading at $0.6984 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRVN stock has decreased by 2.0% and is now trading at $0.6847.
View which stocks have been most impacted by COVID-19.

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Trevena.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. Trevena had a negative trailing twelve-month return on equity of 40.89% and a negative net margin of 1,194.62%. During the same period in the previous year, the company posted ($0.04) EPS.
View Trevena's earnings history.

What price target have analysts set for TRVN?

2 Wall Street analysts have issued 1-year price objectives for Trevena's shares. Their forecasts range from $6.00 to $6.00. On average, they expect Trevena's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 776.3% from the stock's current price.
View analysts' price targets for Trevena or view top-rated stocks among Wall Street analysts.

Who are Trevena's key executives?

Trevena's management team includes the following people:

• Carrie L. Bourdow, President, Chief Executive Officer & Director (LinkedIn Profile)
• Barry Shin, Chief Financial Officer & Senior Vice President
• Mark A. Demitrack, Chief Medical Officer & Senior Vice President
• Angela Bagley, Vice President-Technical Operations
• Michael J. Fossler, VP-Clinical Development & Quantitative Sciences

Who are some of Trevena's key competitors?

Some companies that are related to Trevena include CytomX Therapeutics (CTMX), Evelo Biosciences (EVLO), Rigel Pharmaceuticals (RIGL), Geron (GERN), Provention Bio (PRVB), BELLUS Health (BLU), Aldeyra Therapeutics (ALDX), Aadi Bioscience (AADI), Foghorn Therapeutics (FHTX), Mirum Pharmaceuticals (MIRM), Vaccitech (VACC), Viking Therapeutics (VKTX), Clovis Oncology (CLVS), Altimmune (ALT) and Nabriva Therapeutics (NBRV).
View all of TRVN's competitors.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.76%), Geode Capital Management LLC (1.84%), Morgan Stanley (0.27%), Two Sigma Investments LP (0.13%), Goldman Sachs Group Inc. (0.10%) and LPL Financial LLC (0.10%).
View institutional ownership trends for Trevena.

Which major investors are selling Trevena stock?

TRVN stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, California State Teachers Retirement System, Goldman Sachs Group Inc., New York State Common Retirement Fund, BlackRock Inc., IFP Advisors Inc, The Manufacturers Life Insurance Company , and Citadel Advisors LLC.
View insider buying and selling activity for Trevena or view top insider-selling stocks.

Which major investors are buying Trevena stock?

TRVN stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Two Sigma Investments LP, State Board of Administration of Florida Retirement System, SG Americas Securities LLC, Barclays PLC, LPL Financial LLC, Two Sigma Advisers LP, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Trevena or or view top insider-buying stocks.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $0.68.

How much money does Trevena make?

Trevena has a market capitalization of $112.65 million and generates $3.07 million in revenue each year. The biopharmaceutical company earns $-29.37 million in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

What is Trevena's official website?

The official website for Trevena is www.trevena.com.

Where are Trevena's headquarters?

Trevena is headquartered at 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].